Enhancing SARC-F: Improving Sarcopenia Screening in the Clinical Practice

详细信息    查看全文

• 作者：Thiago Gonzalez Barbosa-Silva ; MD ; MSc^a ; ^{tgbsilva@hotmail.com} ; Ana Maria Baptista Menezes ; MD ; PhD^a ; Renata Moraes Bielemann ; RD ; PhD^a ; Theodore K. Malmstrom ; PhD^b ; Maria Cristina Gonzalez ; MD ; PhD^a ; ^c ; on behalf of Grupo de Estudos em Composi&ccedil ; ã ; o Corporal e Nutri&ccedil ; ã ; o (COCONUT)
• 关键词：Sarcopenia ; screening ; calf circumference ; body composition ; muscle mass ; validation study
• 刊名：Journal of the American Medical Directors Association
• 出版年：2016
• 出版时间：1 December 2016
• 年：2016
• 卷：17
• 期：12
• 页码：1136-1141
• 全文大小：689 K
• 卷排序：17

文摘

To validate the (Brazilian) Portuguese-translated version of the SARC-F questionnaire and to verify its performance in the separate sarcopenia screening and muscle function evaluation contexts. In addition, by associating SARC-F to an anthropometric measurement (as an estimate of muscle mass), to test for improvements in its sarcopenia screening efficacy.DesignCross-sectional study.SettingUrban population of Pelotas, a middle-sized city in Southern Brazil.ParticipantsSubsample of 179 community-dwelling elderly aged 60 years or older derived from a population-based study (COMO VAI?).MeasurementsSarcopenia was evaluated using the European Working Group on Sarcopenia in Older People's diagnostic criteria: dual-energy X-ray absorptiometry, handgrip strength, and walking speed test. Participants also completed SARC-F and their calf circumference (CC) was measured. SARC-F and CC were combined into an original score. The questionnaires' performances were evaluated through receiver operating characteristic curves, sensitivity/specificity analyses, and Pearson χ2.ResultsSarcopenia was identified in 15 (8.4%) participants by the European Working Group on Sarcopenia in Older People's criteria. Areas under the receiver operating characteristic curves of SARC-F were 0.592 (95% confidence interval (CI) 0.445, 0.739) screening for sarcopenia and 0.779 (95% CI 0.710, 0.846) evaluating muscle function (P < .001). The SARC-F+CC association significantly improved SARC-F's sarcopenia screening performance [area under the curve: 0.736 (95% CI 0.575, 0.897); comparing with SARC-F alone: P = .027]. A substantial improvement in sensitivity was achieved without compromising the remaining parameters.ConclusionsDespite the satisfactory performance evaluating muscle function, SARC-F alone has not achieved adequate results as a sarcopenia screening tool. However, the SARC-F+CC association significantly improved SARC-F's sarcopenia screening performance, enabling its use in the clinical practice.